William Blair initiated coverage of Corbus Pharmaceuticals (CRBP) with an Outperform rating.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals: Promising ADC Advancements with CRB-701 and Market Opportunities Amidst Risks
- Promising Potential of Corbus Pharmaceuticals’ CRB-701 in Oncology: A Strong Buy Rating by Andrew Fein
- Corbus Pharmaceuticals Reports Promising Phase 1 Trial Results
- Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
- Corbus Pharmaceuticals announces clinical data for CRB-701
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue